ArticleTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2011
Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light.
Article in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed.
- Article
- Pathogen-reduction technology, good in more than one way for cellular blood components, is replacing irradiation.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2025Review
- Platelet Storage-Problems, Improvements, and New Perspectives.International journal of molecular sciences · 2024Review
- Ultraviolet light and riboflavin accelerates red blood cell dysfunction in vitro and in a guinea pig transfusion model.Blood transfusion = Trasfusione del sangue · 2024Article
- Photodynamic inactivation of antibiotic-resistant bacteria in whole blood using riboflavin photodynamic method.Frontiers in microbiology · 2024Article
- Evaluation of bacterial safety approaches of platelet blood concentrates: bacterial screening and pathogen reduction.Frontiers in medicine · 2024Review
- Emerging Pathogen Threats in Transfusion Medicine: Improving Safety and Confidence with Pathogen Reduction Technologies.Pathogens (Basel, Switzerland) · 2023Review
- Assessing quality of blood components derived from whole blood treated with riboflavin and ultraviolet light and separated with a fully automated device.Blood transfusion = Trasfusione del sangue · 2022Article
- An Outbreak of Japanese Encephalitis Virus in Australia; What Is the Risk to Blood Safety?Viruses · 2022Article
- Seroprevalence of Transfusion Transmissible Infections and Associated Risk Factors in Hospitalized Patients before Transfusion in Jinling Hospital Nanjing University: A Three-Year Retrospective Study.Pathogens (Basel, Switzerland) · 2022Article
- Characterization of the Antibacterial Activity of an SiOAntibiotics (Basel, Switzerland) · 2022Article
- A minimally manipulated preservation and virus inactivation method for amnion/chorion.Frontiers in bioengineering and biotechnology · 2022Article
- Inactivation of human plasma alters the structure and biomechanical properties of engineered tissues.Frontiers in bioengineering and biotechnology · 2022Article
- Analysis of the mechanism of damage produced by thiazole orange photoinactivation in apheresis platelets.Blood transfusion = Trasfusione del sangue · 2021Article
- Antimicrobial blue light for decontamination of platelets during storage.Journal of biophotonics · 2020Article
- Platelet Pathogen Reduction Technologies Alter the MicroRNA Profile of Platelet-Derived Microparticles.Frontiers in cardiovascular medicine · 2020Article
- Pathogen reduction with riboflavin and ultraviolet light induces a quasi-apoptotic state in blood leukocytes.Transfusion · 2019Article
- Pathogen reduction of blood components during outbreaks of infectious diseases in the European Union: an expert opinion from the European Centre for Disease Prevention and Control consultation meeting.Blood transfusion = Trasfusione del sangue · 2019Article
- Evaluation of riboflavin photochemical treatment for inactivation of HCT116 tumor cells mixed in simulative intraoperative salvage blood.Transfusion · 2019Article
- Risk factors, management and prevention of transfusion-related acute lung injury: a comprehensive update.Expert review of hematology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial contamination and emerging infections combined with increased international travel pose a great risk to the safety of the blood supply. Tests to detect the presence of infection in a donor have a 'window period' during which infections cannot be detected but the donor may be infectious. Agents and their transmission routes need to be recognized before specific tests can be developed. Pathogen reduction of blood components represents a means to address these concerns and is a proactive approach for the prevention of transfusion-transmitted diseases. The expectation of a pathogen reduction system is that it achieves high enough levels of pathogen reduction to reduce or prevent the likelihood of disease transmission while preserving adequate cell and protein quality. In addition the system needs to be non-toxic, non-mutagenic and should be simple to use. The Mirasol® Pathogen Reduction Technology (PRT) System for Platelets and Plasma uses riboflavin (vitamin B2) plus UV light to induce damage in nucleic acid-containing agents. The system has been shown to be effective against clinically relevant pathogens and inactivates leukocytes without significantly compromising the efficacy of the product or resulting in product loss. Riboflavin is a naturally occurring vitamin with a well-known and well-characterized safety profile. The same methodology is currently under development for the treatment of whole blood, making pathogen reduction of all blood products using one system achievable. This review gives an overview of the Mirasol PRT System, summarizing the mechanism of action, toxicology profile, pathogen reduction performance and clinical efficacy of the process.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.